YaoGeJu

Public drug landscapesDrug landscape

Pimecrolimus Cream

As of 13 November 2026, for Pimecrolimus Cream, 5 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 0 holders.

Companies, stages and changes, with each record available on this page.

Last 90 days: No longer listed under review: 1 application

Current coverage may be incomplete

Follow for free
Complete CDE snapshot
2026/11/13 06:42
Matching scope
Same generic name; dosage forms and combinations kept separate

US Orange Book listing

The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.

Orange Book source export date: 2026/11/06. Version: 2026-11-06.

Showing 1 of 1 distinct brand names.

A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.

Verified official English dosage form: Cream. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.

Same dosage form

No listings in this group among the displayed brand names.

Other dosage forms of the same ingredient

Brand nameApplicant (source text)Application numberDosage form (source text)Route (source text)Marketing status (source text)Approval date
ELIDEL BAUSCH HEALTH US LLC NDA 021302 · Product no. 001 CREAM TOPICAL HUMAN PRESCRIPTION DRUG 2001/12/13

Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.

Ingredient cross-list details ↗

Which companies are listed, and at what stages?

Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.

Chemical-drug catalogue

Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.

Marketing authorization holderManufacturerApproval numberApprovedStrength / specificationCatalogue category (source text)View source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

NHSA drug codes

Loaded records: 10 distinct approval numbers and 10 companies.

Company / applicantApproval numberStrength / specificationNHSA classNHSA drug codeView source
Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized国药准字H202638711%(15g:0.15g)Category BXD11AXB099F002010101504NHSA
ZHE JIANG HUA HAI PHARMACEUTICALCO.,LTD.国药准字H202641351%(15g:0.15g)Category BXD11AXB099F002010104647NHSA
HAINAN HUALON PHARMACEUTICAL CO.,LTD国药准字H202546131%(10g:0.1g)Category BXD11AXB099F002010105781NHSA
Hubei Cheng Tian Pharma Co., Ltd. romanized国药准字H202642141%(15g:0.15g)Category BXD11AXB099F002010109664NHSA
Jiangsu Ying Ke Biopharmaceutical Co., Ltd. romanized国药准字H202661321% (15g:0.15g)Category BXD11AXB099F002010110137NHSA
MEDA Pharma GmbH & Co. KGH201700031%Category BXD11AXB099F002010178626NHSA
Fu Yuan Pharma Co., Ltd. romanized国药准字H202647751%(15g:0.15g)Category BXD11AXB099F002010180651NHSA
Jiangsu Ziyond Pharmaceutical Co., Ltd.国药准字H202238201%(10g:0.1g)Category BXD11AXB099F002010181475NHSA
Hainan Zhen Dong Bio Technology Co., Ltd. romanized国药准字H202442301%(15g:0.15g)Category BXD11AXB099F002010184633NHSA
Viatris Healthcare GmbH国药准字HJ201700041%Category BXD11AXB099F002020178626NHSA
Jiangsu Ziyond Pharmaceutical Co., Ltd.国药准字H202238201%(10g:0.1g)Category BXD11AXB099F002020181475NHSA
Viatris Healthcare GmbH国药准字HJ201700041%Category BXD11AXB099F002030178626NHSA
Jiangsu Ziyond Pharmaceutical Co., Ltd.国药准字H202238201%(10g:0.1g)Category BXD11AXB099F002030181475NHSA

Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.

Current under-review applications

Loaded records: 5 filings and 5 distinct first applicants.

Generic 5

Current under-review applications
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Shanxi Ze Chen Pharmaceuticals Technology Co., Ltd. romanized; Hunan Jiudian Pharmaceutical Co., LtdCYHS2600929Generic2026/04/23Not stated by sourceCDE
Chongqing Wan Lin Biopharmaceuticals Technology Co., Ltd. romanized; Hunan Jiudian Pharmaceutical Co., LtdCYHS2600460Generic2026/02/13Not stated by sourceCDE
Zhejiang Bai Dai Pharmaceuticals Technology Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanizedCYHS2504504Generic2025/12/31Not stated by sourceCDE
Shanghai Xin Ya Pharma Min Xing Co., Ltd. romanized; Hainan Hai Shen Tong Zhou Pharmaceutical Co., Ltd. romanizedCYHS2503311Generic2025/09/06Not stated by sourceCDE
Shanghai Zhao Hui Pharma Co., Ltd. romanizedCYHS2501744Generic2025/05/14Not stated by sourceCDE
New generic filings in 2026

Loaded records: 2 filings and 2 distinct first applicants.

New generic filings in 2026
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Shanxi Ze Chen Pharmaceuticals Technology Co., Ltd. romanized; Hunan Jiudian Pharmaceutical Co., LtdCYHS2600929Generic2026/04/23Not stated by sourceCDE
Chongqing Wan Lin Biopharmaceuticals Technology Co., Ltd. romanized; Hunan Jiudian Pharmaceutical Co., LtdCYHS2600460Generic2026/02/13Not stated by sourceCDE
API registrations

Non-component matches: 1 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.

NameCompany / applicantRegistration numberStatusName matchSource update dateView source
吡美莫司 · No verified English nameSichuan Nuo Yi Sheng Pharma Co., Ltd. romanizedY20250000822IExact ingredient2025/08/22CDE
吡美莫司 · No verified English nameBo Rui Pharmaceutical (Suzhou) Co., Ltd. romanizedY20210000257AExact ingredient2024/04/19CDE

A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.

What changed recently?

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.

Trial registration does not mean an application will follow.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

  1. 2026/11/12No longer listed under review

    Shanghai Shyndec Pharmaceutical Co., Ltd.

    CYHS2500202

    Fact date: 2026/11/12 · Site observation date: 2026/11/12

    Accepted: 2025/01/10

    not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked

    View source ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

Full API register
Last successful update: 2026/11/13 06:41
NHSA drug codes
Last successful update: 2026/11/05 06:45

The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.

NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Drug Clinical Trial Registry and Information Disclosure Platform
Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete

Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.

Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Free follow

Follow changes to Pimecrolimus Cream

Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.

Confirmation links expire in 7 days. No digest is sent before confirmation; existing follows are not duplicated.

Sign in to choose products